Takeda Pharmaceutical Company Limited Stock
Stocks
4502
JP3463000004
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Japan Exchange
04:30:00 27/08/26 pm AEST
|
5-day change | 1st Jan Change | ||
| 5,809.00 JPY | -0.87% |
|
+0.69% | +20.14% |
| 24/08 | FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome | RE |
| 24/08 | Takeda's Orzeryful Approved in Japan as First Treatment Targeting Narcolepsy Type 1 | MT |
| Market Cap | 9,357B 58.71B 50.39B 47.3B 43.2B 81.53B 5,600B 81.92B 560B 217B 2,825B 220B 216B | P/E 2027 * |
47x | P/E 2028 * | 30.1x |
|---|---|---|---|---|---|
| Enterprise Value | 13,259B 83.2B 71.41B 67.02B 61.21B 116B 7,935B 116B 793B 307B 4,003B 312B 306B | EV / Sales 2027 * |
2.83x | EV / Sales 2028 * | 2.74x |
| Free-Float |
99.26% | Yield 2027 * |
3.49% | Yield 2028 * | 3.56% |
Last Transcript : Takeda Pharmaceutical Company Limited
| 1 day | -0.87% | ||
| 1 week | +0.69% | ||
| Current month | +5.37% | ||
| 1 month | +0.69% | ||
| 3 months | +14.80% | ||
| 6 months | +1.36% | ||
| Current year | +20.14% |
| 1 week | 5,729 |  | 5,859 |
| 1 month | 5,225 | | 5,903 |
| Current year | 4,710 | | 6,033 |
| 1 year | 4,102 | | 6,033 |
| 3 years | 3,852 | | 6,033 |
| 5 years | 2,993 | | 6,033 |
| 10 years | 2,894.5 | | 6,693 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 01/01/2025 | |
Mikuno Furuta
DFI | Director of Finance/CFO | 48 | 01/04/2024 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 47 | 01/02/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Andrew Plump
BRD | Director/Board Member | 60 | 01/06/2015 |
Steven Gillis
BRD | Director/Board Member | 73 | 01/01/2019 |
Mikuno Furuta
BRD | Director/Board Member | 48 | 01/06/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 19/8/26 | Sell | Chief Technology Officer | -19,651 | 0.0012% | ||
| 18/8/26 | Sell | Head of Human Resources | -12,980 | 0.0008% | ||
| 11/8/26 | Sell | Pres., Global Supply & Quality | -20,363 | 0.0013% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.87% | +0.69% | +31.96% | +29.90% | 58.71B | |
| -1.07% | -7.10% | +61.60% | +114.83% | 1,060B | |
| -2.04% | -1.25% | +52.98% | +62.41% | 651B | |
| -1.61% | -1.15% | +26.18% | +79.22% | 465B | |
| -1.56% | -2.12% | +38.58% | +40.42% | 365B | |
| -1.99% | -0.87% | +22.81% | +38.45% | 300B | |
| -0.97% | +0.85% | +2.36% | +12.48% | 258B | |
| -1.04% | -0.46% | +52.06% | +71.75% | 238B | |
| -3.28% | -0.39% | -17.30% | -54.37% | 210B | |
| -0.90% | +0.33% | +29.05% | +92.67% | 184B | |
| Average | -1.42% | -0.44% | +30.03% | +48.78% | 378.91B | |
| Weighted average by Cap. | -1.30% | -2.10% | +39.44% | +66.79% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 4,687B 29.41B 25.24B 23.69B 21.64B 40.84B 2,805B 41.03B 280B 109B 1,415B 110B 108B | 4,766B 29.91B 25.67B 24.09B 22B 41.53B 2,852B 41.73B 285B 110B 1,439B 112B 110B |
| Net income | 194B 1.22B 1.04B 980M 895M 1.69B 116B 1.7B 11.59B 4.49B 58.51B 4.57B 4.47B | 318B 1.99B 1.71B 1.61B 1.47B 2.77B 190B 2.78B 18.99B 7.36B 95.87B 7.48B 7.32B |
| Net Debt | 3,902B 24.49B 21.02B 19.73B 18.02B 34B 2,335B 34.16B 233B 90.47B 1,178B 91.93B 89.94B | 3,701B 23.22B 19.93B 18.71B 17.09B 32.25B 2,215B 32.4B 221B 85.8B 1,117B 87.2B 85.3B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 27/08/26 | JPY 5,809.00 | -0.87% | 2,556,600 |
| 26/08/26 | JPY 5,860.00 | +0.81% | 3,073,000 |
| 25/08/26 | JPY 5,813.00 | +0.28% | 3,025,100 |
| 24/08/26 | JPY 5,797.00 | +0.57% | 2,568,100 |
| 21/08/26 | JPY 5,764.00 | -1.05% | 3,177,000 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4502 Stock
Select your edition
All financial news and data tailored to specific country editions
